Trusted Resources: Evidence & Education
Scientific literature and patient education texts
The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy
source: European Thyroid Journal
authors: Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WMsummary/abstract:
Graves’ orbitopathy (GO) is the main extrathyroidal manifestation of Graves’ disease, though severe forms are rare. Management of GO is often suboptimal, largely because available treatments do not target pathogenic mechanisms of the disease. Treatment should rely on a thorough assessment of the activity and severity of GO and its impact on the patient’s quality of life. Local measures (artificial tears, ointments and dark glasses) and control of risk factors for progression (smoking and thyroid dysfunction) are recommended for all patients.
In mild GO, a watchful strategy is usually sufficient, but a 6-month course of selenium supplementation is effective in improving mild manifestations and preventing progression to more severe forms. High-dose glucocorticoids (GCs), preferably via the intravenous route, are the first line of treatment for moderate-to-severe and active GO. The optimal cumulative dose appears to be 4.5-5 g of methylprednisolone, but higher doses (up to 8 g) can be used for more severe forms.
Shared decision-making is recommended for selecting second-line treatments, including a second course of intravenous GCs, oral GCs combined with orbital radiotherapy or cyclosporine, rituximab or watchful waiting. Rehabilitative treatment (orbital decompression surgery, squint surgery or eyelid surgery) is needed in the majority of patients when GO has been conservatively managed and inactivated by immunosuppressive treatment.organization: University of Insubria, Italy; Catholic University of Louvain, Belgium; Aristotle University of Thessaloniki, Greece; Universitätsklinikum Essen, Germany; Johannes Gutenberg University Medical Center, Germany; University of Pisa, Italy; Newcastle upon Tyne Hospitals NHS Foundation Trust, UK; University of Milan, Italy; University of Amsterdam, Netherlands
A Validated Tool Can Predict Risk of Developing Thyroid Eye Disease During Antithyroid Drug Treatment of Graves’ D...Over-activity of the thyroid gland, call...
Controversies in the Pharmacological Treatment of Graves’ Disease in ChildrenGraves' disease (GD) is a disorder, in w...
Glucocorticoid Regimens for Prevention of Graves’ Ophthalmopathy Progression Following Radioiodine Treatment: ...Background: Glucocorticoid (GC) therapy...
Thyroid Eye DiseaseThyroid eye disease may occur in patient...
Adults With Thyroid Disease Lack Knowledge of Ophthalmologic ThreatsAdults with thyroid eye disease or Grave...
Impact of Potassium Iodide on Thyroidectomy for Graves’ Disease: Implications for Safety and Operative Difficu...Background: Potassium iodide (KI) is of...
The Second Antithyroid Drug Treatment is Effective in Relapsed Graves’ Disease Patients: A Median 11-Year Foll...Background: Antithyroid drug (ATD) is a...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.